William Blair & Company
AGRX

William Blair & Company’s Agile Therapeutics AGRX Stock Holding History

William Blair & Company’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6
Closed -$68K – 1283
2016
Q1 		$68K Buy
+6
New +$77.5K ﹤0.01% 1145

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

William Blair & Company's AGRX Position: Q2 2016 in Review

William Blair & Company sold out of Agile Therapeutics (AGRX) in Q2 2016, closing a stake of 6 shares — an estimated $68K sold.

William Blair & Company first reported a position in AGRX in Q1 2016 and held it in 1 quarter. The position peaked at $68K in Q1 2016. 50 funds tracked by Wall St. Rank hold AGRX as of Q2 2016.

  • William Blair & Company reported no remaining Agile Therapeutics position as of Q2 2016 after selling out during the quarter.
  • William Blair & Company sold 6 Agile Therapeutics shares in Q2 2016, an estimated $68K.
  • William Blair & Company first reported a position in Agile Therapeutics in Q1 2016 and held it in 1 quarter.
  • William Blair & Company's Agile Therapeutics position peaked at $68K in Q1 2016.
  • 50 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2016.

Based on William Blair & Company's 13F filing for Q2 2016, filed 8 Aug 2016.